pS2 as a Prognostic Factor in Breast Cancer
Author Information
Author(s): A.M. Thompson, R.A. Hawkins, R.A. Elton, C.M. Steel, U. Chetty, D.C. Carter
Primary Institution: University Department of Surgery, Royal Infirmary, Edinburgh
Hypothesis
Can pS2 mRNA expression in primary breast cancer be related to patient prognosis and other established prognostic factors?
Conclusion
pS2 mRNA expression is significantly associated with a good prognosis in primary breast cancer patients.
Supporting Evidence
- pS2 mRNA expression was detected in 32% of breast cancers.
- Patients with pS2 mRNA expression had only a 4% recurrence rate.
- pS2 expression was significantly associated with moderate/high oestrogen receptor content (P = 0.045).
- Only 1 out of 13 patients with pS2 expression had disease recurrence compared to 45% without it.
Takeaway
This study found that a specific gene called pS2 can help doctors predict how well a breast cancer patient will do, especially if they have certain types of tumors.
Methodology
The study examined pS2 mRNA expression in 78 untreated primary breast cancers and related it to disease behavior and known prognostic factors.
Limitations
The study did not include pathological grade in the assessment.
Participant Demographics
78 female patients aged 34-84, with 26 premenopausal and 52 postmenopausal.
Statistical Information
P-Value
0.015
Confidence Interval
(1.14, 379)
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website